2,103 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,141 shares of the biopharmaceutical company’s stock after selling 2,103 shares during the period. Fifth Third Bancorp’s holdings in Regeneron Pharmaceuticals were worth $20,580,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $26,000. Armstrong Advisory Group Inc. raised its holdings in Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 28 shares in the last quarter. Activest Wealth Management raised its holdings in Regeneron Pharmaceuticals by 780.0% during the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 39 shares in the last quarter. Alpine Bank Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at about $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at about $29,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on REGN shares. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $660.00 to $978.00 in a report on Thursday, October 15th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a research note on Monday, November 2nd. Raymond James Financial lifted their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. The Goldman Sachs Group upped their price objective on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Guggenheim upped their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $898.97.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine Poon sold 7,830 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the sale, the director directly owned 5,219 shares in the company, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Larosa sold 4,466 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total value of $4,311,878.34. Following the completion of the sale, the executive vice president directly owned 38,906 shares in the company, valued at $37,563,353.94. This trade represents a 10.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 27,028 shares of company stock valued at $25,025,950 in the last 90 days. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Trading Up 0.4%

Shares of REGN opened at $955.47 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $98.84 billion, a P/E ratio of 21.10, a PEG ratio of 1.26 and a beta of 0.10. The firm’s 50-day moving average is $816.17 and its two-hundred day moving average is $747.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same period last year, the firm earned $11.83 EPS. The company’s revenue for the quarter was up 36.3% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is currently 8.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.